Thymic carcinoma surgery: Difference between revisions

	Thymic Carcinoma Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Thymic carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Thymic carcinoma surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Google Images
American Roentgen Ray Society Images of Thymic carcinoma surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Thymic carcinoma surgery
CDC on Thymic carcinoma surgery
Thymic carcinoma surgery in the news
Blogs on Thymic carcinoma surgery
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Thymic carcinoma surgery

Revision as of 16:14, 4 January 2016

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Treatment options for thymic carcinoma include the following:

For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention.
For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given.
Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy.
Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments.
Patients with metastatic disease may respond to combination chemotherapy.

@@ Line 9: / Line 9: @@
 *Surgery
 *Radiation
-Multimodality approach, such as:
-*Surgical resection
-*Radiation therapy
 *Cisplatin-based chemotherapy
-For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention. For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given.[2] Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy. Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments. Patients with metastatic disease may respond to combination chemotherapy.
+*For patients with clinically resectable disease, surgical resection is often the initial therapeutic intervention.
+*For clinically borderline or frankly unresectable lesions, neoadjuvant (preoperative) chemotherapy or thoracic radiation therapy, or both, is given.
+*Patients presenting with locally advanced disease should be carefully evaluated and undergo multimodality therapy.
+*Patients with poor performance status and high associated operative risks are generally not considered for these types of aggressive treatments.
+*Patients with metastatic disease may respond to combination chemotherapy.
 ==References==
 {{Reflist|2}}
 [[Category:Disease]]